

Supplementary figure 2

C57B6/J mice were injected with 1 x 10^5 E0771 cells into the 4th mammary fat pad and palpable tumors were i.t. injected with vehicle or 3M-052 on day 13 post-inoculation and **(a)** overall TIL proportions at endpoint and **(b)** NK1.1$^+$ cells were assessed for CD69 expression. BALB/c mice were injected with 1 x 10^5 4T1.2 cells into the 4th mammary fat pad and palpable tumors were i.t. injected with vehicle or 3M-052 on day 5 post-inoculation. **(c)** For non-resection mice at endpoint primary tumor weights (mg) were recorded. On day 8, CD69 expression of **(d)** CD3$^+$CD8$^+$ T cells, **(e)** CD3$^+$CD4$^+$ T cells and **(f)** TCRβ$^-$NKp46$^+$ cells was assessed from peripheral blood by flow cytometry. **(g)** Day 12 resected primary tumors from i.t vehicle or 3M-052 treated mice; **(h)** representative images shown. InForm software analysis of PD-1 staining from Figure 1c: **(i)** PD-1 positivity and **(j)** H-Score. Experiments were independently repeated twice, and representative data are shown. **(a) (b)** *n* = 5 mice/group. **(c)** *n* = 4 mice/group. **(d) (e) (f)** *n* = 6 mice/group. **(g)** *n* = 10 mice/group, **(h) (i) (j)** *n* = 3 mice/group. Statistical analysis performed by Student's two-tailed *t* tests. Error bars are SEM. *, $P < 0.05$; **, $P < 0.01$; ****, $P < 0.0001$.